3RDZ image
Entry Detail
PDB ID:
3RDZ
Title:
Crystal Structure of rBTI-trypsin complex at 2.26 angstrom resolution
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2011-04-02
Release Date:
2011-07-06
Method Details:
Experimental Method:
Resolution:
2.26 Å
R-Value Free:
0.22
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Cationic trypsin
Chain IDs:A, C (auth: B)
Chain Length:223
Number of Molecules:2
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Description:BWI-1=PROTEASE inhibitor/trypsin inhibitor
Chain IDs:B (auth: C), D
Chain Length:79
Number of Molecules:2
Biological Source:Fagopyrum esculentum
Ligand Molecules
Primary Citation
Conformational Changes of rBTI from Buckwheat upon Binding to Trypsin: Implications for the Role of the P(8)' Residue in the Potato Inhibitor I Family
Plos One 6 e20950 e20950 (2011)
PMID: 21698291 DOI: 10.1371/journal.pone.0020950

Abstact

BWI-1 (buckwheat trypsin inhibitor), a member of the potato inhibitor I family, suppresses the growth of T-acute lymphoblastic leukemia cells and induces apoptosis in human solid tumor cell lines. Here, we report the crystal structure of rBTI (recombinant buckwheat trypsin inhibitor), a recombinant protein of BWI-1, at 1.84 Å resolution and the structure of rBTI in complex with bovine trypsin at 2.26 Å resolution. A conformational change of Trp53 at the P(8)' position in rBTI was observed upon its binding to trypsin, which is not seen in other members of the potato inhibitor I family reported previously. The role of the P(8)' residue in the potato inhibitor I family was examined by measuring the association and dissociation rates of four rBTI mutants with different substitutions at the P(2) and P(8)' positions when binding to trypsin. One of the mutants, P44T, was found to be a much stronger inhibitor than wild-type rBTI, with a picomolar (pM) dissociation constant. Our results could provide valuable insights for designing a new rBTI-based antitumor drug in the future.

Legend

Protein

Chemical

Disease

Primary Citation of related structures